

# Activation of Cdh1-dependent APC is required for G<sub>1</sub> cell cycle arrest and DNA damage-induced G<sub>2</sub> checkpoint in vertebrate cells

Tamotsu Sudo<sup>1</sup>, Yosuke Ota<sup>1</sup>, Shuji Kotani<sup>2</sup>, Mitsuyoshi Nakao<sup>1</sup>, Yasunari Takami<sup>3</sup>, Shunichi Takeda<sup>4</sup> and Hideyuki Saya<sup>1,5</sup>

<sup>1</sup>Department of Tumor Genetics and Biology, Kumamoto University School of Medicine, 2-2-1 Honjo, Kumamoto 860-0811,

<sup>2</sup>Bioinformatic Group, Genomic Science Center, Riken, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama City, Kanagawa 230-0045,

<sup>3</sup>Department of Biochemistry, Miyazaki Medical College, Kihara, Kiyotake, Miyazaki 889-1692 and <sup>4</sup>Department of Radiation Genetics, Faculty of Medicine, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan

<sup>5</sup>Corresponding author  
e-mail: hsaya@gpo.kumamoto-u.ac.jp

**Anaphase-promoting complex (APC) is activated by two regulatory proteins, Cdc20 and Cdh1. In yeast and *Drosophila*, Cdh1-dependent APC (Cdh1-APC) activity targets mitotic cyclins from the end of mitosis to the G<sub>1</sub> phase. To investigate the function of Cdh1 in vertebrate cells, we generated clones of chicken DT40 cells disrupted in their *Cdh1* loci. Cdh1 was dispensable for viability and cell cycle progression. However, similarly to yeast and *Drosophila*, loss of *Cdh1* induced unscheduled accumulation of mitotic cyclins in G<sub>1</sub>, resulting in abrogation of G<sub>1</sub> arrest caused by treatment with rapamycin, an inducer of p27<sup>Kip1</sup>. Furthermore, we found that *Cdh1*<sup>-/-</sup> cells fail to maintain DNA damage-induced G<sub>2</sub> arrest and that Cdh1-APC is activated by X-irradiation-induced DNA damage. Thus, activation of Cdh1-APC plays a crucial role in both cdk inhibitor-dependent G<sub>1</sub> arrest and DNA damage-induced G<sub>2</sub> arrest.**

**Keywords:** Cdc27/DT40/mitotic cyclin/p27/rapamycin

## Introduction


The ubiquitin–proteasome system for destruction of proteins plays a crucial role in the regulation of cell cycle progression (Kramer *et al.*, 2000). Anaphase-promoting complex/cyclosome (APC) is a multisubunit complex that functions as a ubiquitin ligase specific for various cell cycle proteins, including cyclin B, cyclin A, mitotic kinases, inhibitors of anaphase, spindle-associated proteins and inhibitors of DNA replication (King *et al.*, 1995, 1996; Sudakin *et al.*, 1995; Cohen-Fix and Koshland, 1997; Juang *et al.*, 1997). The activity of APC is tightly regulated to control cell cycle progression, being high from late mitosis until late in the G<sub>1</sub> phase but low in S, G<sub>2</sub> and early mitosis in yeast and mammalian cells.

Genetic and biochemical analyses in yeast, *Drosophila* and *Xenopus* have revealed that the function of the APC is regulated by two types of WD-40 repeat-containing protein, Cdc20/fizzy (fzy)/p55CDC and Hct1/srw1/fizzy-related (fzr)/Cdh1, in a substrate-specific manner. In

metaphase, the Cdc20-activated APC (Cdc20-APC) ubiquitylates anaphase inhibitors, such as Pds1 in budding yeast (Visintin *et al.*, 1997), Cut2 in fission yeast (Funabiki *et al.*, 1996) and securin in *Xenopus* (Zou *et al.*, 1999). Proteolysis of these anaphase inhibitors releases their binding partner Esp1 (in budding yeast), which in turn results in the cleavage of cohesin, allowing sister chromatid separation for transition from metaphase to anaphase (Uhlmann *et al.*, 1999). It has also been reported that Cdc20 is essential not only for sister chromatid separation but also for proteolysis of mitotic cyclin clb2 in budding yeast (Lim *et al.*, 1998; Yeong *et al.*, 2000). These data suggest that Cdc20-APC is required for both initiation of anaphase and exit from mitosis. On the other hand, Hct1/srw1/fzr/Cdh1 is believed to maintain APC activity from the end of mitosis until the end of G<sub>1</sub>. In budding yeast, clb2 is highly stabilized in G<sub>1</sub> phase in Hct1 mutants (Schwab *et al.*, 1997; Visintin *et al.*, 1997). Furthermore, in *Drosophila*, loss of *fzr* causes the unscheduled accumulation of mitotic cyclins in the G<sub>1</sub> phase, following an extra division cycle in the epidermis (Sigrist and Lehner, 1997). These findings suggest that the Hct1/srw1/fzr/Cdh1-dependent APC activity targets mitotic cyclins for destruction from the end of mitosis to the G<sub>1</sub> phase but is dispensable for metaphase–anaphase transition and exit from mitosis. However, it remains unclear whether this is also true in higher vertebrates.

Maintenance of genomic integrity after DNA damage depends on cell cycle checkpoints, which control a signaling system that produces changes in the activity of cyclin-dependent kinases (cdks), resulting in a delay in cell cycle progression. Arrest in G<sub>1</sub> is considered to prevent aberrant replication of damaged DNA, and arrest in G<sub>2</sub> allows cells to avoid segregation of defective chromosomes. G<sub>1</sub> arrest after DNA damage is induced primarily by stabilization of p53 (Lakin and Jackson, 1999). However, it has been reported recently that the initial step in the DNA damage-induced G<sub>1</sub> arrest is p53 independent and mediated by cyclin D1 proteolysis, which possibly is carried out by the APC (Agami and Bernards, 2000). This observation suggests the possibility that the APC is activated in response to DNA damage and contributes to the checkpoint activation.

In this study, we have investigated the role of Cdh1 in higher vertebrates by generating *Cdh1*<sup>-/-</sup> cells using the hyper-recombinogenic chicken B-cell line DT40. Phenotypic analysis of the mutant clones revealed that Cdh1 is dispensable for viability and cell cycle progression but plays a crucial role in down-regulation of mitotic cyclins in the G<sub>1</sub> phase in vertebrate cells, similarly to yeast and *Drosophila*. Therefore, loss of Cdh1 induced unscheduled accumulation of mitotic cyclins in G<sub>1</sub>, resulting in abrogation of G<sub>1</sub> arrest caused by rapamycin treatment, which is known to activate expression of p27<sup>Kip1</sup>.




**Fig. 1.** Generation of *Cdh1*<sup>-/-</sup> clones. (A) Schematic representation of a partial restriction map of the chicken *Cdh1* locus, the two gene disruption constructs and the configuration of the targeted loci. Black boxes indicate the position of exons. The box designated 'probe' represents the region used for Southern blotting. Primer sites for PCR screening are indicated by arrowheads. Relevant *Bam*HI restriction enzyme sites are shown. (B) PCR analysis of genomic DNA from targeted cells of the genotypes indicated. Genomic DNAs from wild-type (+/+), heterozygous (+/-) and homozygous mutant (-/-) clones (clones 1 and 2) were amplified using three sets of primers (p2-p4, p1-p3 and p1-p5) depicted in (A). (C) Southern blot analysis of wild-type (+/+), heterozygous (+/-) and homozygous mutant (-/-) clones (clones 1 and 2). *Bam*HI-digested genomic DNA was hybridized with the labeled probe DNA depicted in (A). New 4 kb *Bam*HI fragments were detected with the probe following targeted integration of the knockout constructs. (D) Ethidium bromide-stained agarose gel showing RT-PCR products of the full-length *Cdh1* mRNAs were isolated from wild-type (+/+), heterozygous (+/-) and homozygous mutant (-/-) clones. GAPDH cDNA was used as control amplification to ensure the successful completion of cDNA synthesis and the PCR.

Furthermore, our results identify an unexpected role for Cdh1-APC in the G<sub>2</sub> checkpoint activated by X-irradiation-induced DNA damage.

## Results

### *Cdh1* targeting constructs and generation of *Cdh1*-deficient DT40 clones

Chicken *Cdh1* cDNA was isolated by PCR using primers specific for human *Cdh1* from the chicken cDNAs. Based on the sequences of chicken *Cdh1* cDNA, ~7 kb of the chicken *Cdh1* locus was amplified by long-range PCR using genomic DNA extracted from DT40 cells as a template. Either the histidinol (his) or the blasticidin (bsr) resistance gene was inserted between sequences of 4 and 3 kb length (Figure 1A). Targeted integration of these constructs disrupts the reading frame of the *Cdh1* gene at the first WD repeat. Targeted events were examined by PCR, Southern blotting analysis and RT-PCR (Figure 1B, C and D). We isolated two viable *Cdh1*<sup>-/-</sup> clones (clones 1 and 2), and the proliferative properties of *Cdh1*<sup>-/-</sup> clones, in comparison with wild-type cells, were monitored by using growth curves and cell cycle analysis. The growth curves of the *Cdh1*<sup>-/-</sup> clones were indistinguishable from that of wild-type cells, which divided approximately every 8 h (Figure 2A). Fluorescence-activated cell sorting (FACS) analysis showed that the cell cycle distributions were the same in both genotypes (Figure 2B). These data indicate that the *Cdh1* gene is dispensable for viability and




**Fig. 2.** Proliferative characteristics of wild-type and *Cdh1*<sup>-/-</sup> DT40 cells. (A) Representative growth curves in wild-type cells (filled circles), *Cdh1*<sup>-/-</sup> clone 1 (filled triangles) and *Cdh1*<sup>-/-</sup> clone 2 (filled squares). Error bars show the standard error of the mean for three independent experiments. (B) Cell cycle distribution of wild-type DT40 cells and *Cdh1*<sup>-/-</sup> clones as measured by BrdU incorporation and DNA content by FACS analysis. Cells were pulse-labeled for 10 min before harvest, and subsequently stained with FITC-anti-BrdU to detect BrdU incorporation (vertical axis, log scale) and propidium iodide to detect total DNA (horizontal axis, linear scale). The upper gate identifies cells incorporating BrdU (S phase), the lower left gate identifies G<sub>1</sub> cells and the lower right gate displays G<sub>2</sub>/M cells. Numbers show the percentages of cells falling in each gate.

proliferation of DT40 cells. Low stringency Southern blot analysis using a *Cdh1* probe did not detect any significant signal besides the *Cdh1* gene (data not shown), suggesting that there is no additional *Cdh1*-related gene that may act redundantly, masking phenotypes of knockout cells.

### Loss of *Cdh1* results in unscheduled accumulation of mitotic cyclins in the G<sub>1</sub> phase

In yeasts (budding and fission) and *Drosophila*, loss of *hct1*, *ste9* and *fzr*, which are Cdh1 homologs, results in ectopic retention of mitotic cyclins in the G<sub>1</sub> phase (Schwab *et al.*, 1997; Sigrist and Lehner, 1997; Yamaguchi *et al.*, 1997; Kitamura *et al.*, 1998). We therefore investigated the protein levels of chicken mitotic cyclins, cyclin A and cyclin B, in wild-type and *Cdh1*<sup>-/-</sup> DT40 cells at different time points after release from nocodazole-induced metaphase block. FACS analysis showed that both genotypes were arrested in metaphase by nocodazole treatment and progress into G<sub>1</sub> from M phase after release (Figure 3A). Immunoblot analysis revealed that the protein levels of both mitotic cyclins were significantly reduced as the G<sub>1</sub> phase approached in wild-type cells. In contrast, in *Cdh1*<sup>-/-</sup> cells, the protein levels of mitotic cyclins failed to decline, resulting in ectopic accumulation of cyclin A and cyclin B in the G<sub>1</sub> phase (Figure 3B), which is consistent with previous findings observed in yeast and *Drosophila*. These data suggest that Cdh1 takes part in the degradation of mitotic




**Fig. 3.** Cdh1-deficient cells have unscheduled accumulation of mitotic cyclins in the G<sub>1</sub> phase. (A) Cells, as indicated, were synchronized at metaphase by treatment with nocodazole for 10 h. At the indicated time points after release from nocodazole block, cells were harvested and analyzed by FACS. (B) The amounts of mitotic cyclins in wild-type and *Cdh1*<sup>-/-</sup> DT40 cells. Cells harvested in the experiment described in (A) were analyzed by immunoblotting with anti-cyclin A and B antibodies. The corresponding Ku70 levels are shown as a loading control.

cyclins from M to G<sub>1</sub> phase but is dispensable for exit from mitosis in higher vertebrates as well as in yeasts and *Drosophila*. It is noteworthy that mitotic cyclins are degraded to some extent in *Cdh1*<sup>-/-</sup> cells (Figure 3B), and this Cdh1-independent degradation of mitotic cyclins may be sufficient for cells to exit mitosis.

#### **Cdh1-deficient cells delay exit from mitosis**


Although Cdh1 is dispensable for metaphase–anaphase transition and exit from mitosis, we examined whether loss of Cdh1 affects the duration of the mitotic phase. Wild-type or *Cdh1*<sup>-/-</sup> cells were synchronized at metaphase by treatment with nocodazole for 10 h. At different times after release from nocodazole block, the frequency of mitotic cells was determined by immunostaining of MPM-2 antigen, which is generally thought to represent mitotic phosphoproteins (Davis *et al.*, 1983). At 45 min after release from metaphase block, ~40–45% of *Cdh1*<sup>-/-</sup> cells remained in a mitotic state with positive MPM-2 staining, compared with only 20% MPM-2-positive cells in the wild type (Figure 4A). These observations suggest that Cdh1-deficient cells delay exit from mitosis. Furthermore, cytological examination of asynchronously growing cultures revealed that *Cdh1*<sup>-/-</sup> cells showed a significant increase in the number of cells in the mitotic phases, particularly in anaphase and telophase (Figure 4B), suggesting that the late mitotic phase is prolonged in *Cdh1*<sup>-/-</sup> cells. Taken together, Cdh1 is not essential for cell viability but plays a regulatory role in transition from late mitotic phase to G<sub>1</sub>.



**Fig. 4.** Exit from mitosis with delay in Cdh1-deficient cells. (A) After release from nocodazole treatment, as described in Figure 3A, cells were immunostained with MPM-2 antibody and analyzed by FACS. The graph displays the percentage of positively stained cells at the time indicated in wild-type cells (filled circles), *Cdh1*<sup>-/-</sup> clone 1 (filled triangles) and *Cdh1*<sup>-/-</sup> clone 2 (filled squares). The rate of positively stained cells was 100% at the time before release. Error bars show the standard error of the mean for three independent experiments. (B) The percentage of cells at mitotic phase (left panel) and at anaphase/telophase (right panel) in asynchronously growing wild-type DT40 cells and two *Cdh1*<sup>-/-</sup> clones. Chromatin is visualized by staining cells with aceto-orcein, with which by its strong staining mitotic condensed chromatin and chromatin segregation were easily identified. Columns and bars represent the mean and SD obtained from three independent experiments. Statistical differences were determined with Student's *t*-test; \**P* < 0.05.

#### **Ectopic retention of mitotic cyclins abrogates G<sub>1</sub> arrest in Cdh1<sup>-/-</sup> cells**

During embryogenesis in *Drosophila*, *fzr*, a homolog of Cdh1, was shown to be required for removal of mitotic cyclin during G<sub>1</sub> when proliferation of embryonic epidermal cell stops. In *fzr*-deficient embryos, epidermal cells progress through an extra division cycle without stopping in G<sub>1</sub> after the terminal mitosis (mitosis 16). This defect is found to be caused by failure to degrade mitotic cyclins due to loss of *fzr* (Sigrist and Lehner, 1997). Since our *Cdh1*<sup>-/-</sup> DT40 cells appeared to have an unscheduled accumulation of mitotic cyclins in the G<sub>1</sub> phase (Figure 3B), we attempted to investigate whether loss of Cdh1 function affects G<sub>1</sub> arrest in higher vertebrates, as well as in *Drosophila*. During *Drosophila* embryogenesis, p27<sup>DAP</sup>, an inhibitor of cyclin E–cdk2, was shown to be expressed before mitosis 16 and to induce G<sub>1</sub> arrest after completion of cycle 16 in epidermal cells (Lane *et al.*, 1996). Unscheduled accumulation of mitotic cyclin by loss of *fzr*, therefore, appears to overcome the p27<sup>DAP</sup>-induced G<sub>1</sub> arrest, resulting in progression through an extra division cycle (Du and Dyson, 1999). p27<sup>Kip1</sup>, a vertebrate homolog



**Fig. 5.** Abrogation of rapamycin-induced G<sub>1</sub> arrest in *Cdh1*<sup>-/-</sup> cells. **(A)** Expression of p27<sup>Kip1</sup>, pRb, cyclin A and cyclin B in wild-type and *Cdh1*<sup>-/-</sup> DT40 cells treated with 100 nM rapamycin for 36 or 72 h. The corresponding Ku70 levels are shown as a loading control. 'AS' indicates extracts from asynchronously proliferating cells. **(B)** Wild type, *Cdh1*<sup>-/-</sup> cells and *Cdh1*<sup>-/-</sup> cells expressing the human *Cdh1* transgene were treated with 100 nM rapamycin for 72 h. Cells were harvested and analyzed by FACS. **(C)** G<sub>1</sub> arrest was induced in rapamycin-treated *Cdh1*<sup>-/-</sup> cells by treatment with olomoucine, a specific inhibitor for cdk2. Wild-type and *Cdh1*<sup>-/-</sup> cells were treated with 100 nM rapamycin for 48 h (upper panels). Thereafter, DMSO (control) or olomoucine (100 mM) was added to the culture medium and incubated for another 24 h. Cells were harvested and analyzed by FACS. Cells were pulse-labeled for 10 min before harvest, and subsequently stained with FITC-anti-BrdU to detect BrdU incorporation and propidium iodide to detect total DNA. **(D)** Cell extracts of the wild-type and *Cdh1*<sup>-/-</sup> DT40 cells were harvested after rapamycin treatment for 72 h and immunoprecipitated with anti-p27<sup>Kip1</sup> antibody or anti-cyclin E antibody. Cyclin A and cyclin E co-immunoprecipitated with p27<sup>Kip1</sup> were detected by immunoblotting with their specific antibodies. Immunoprecipitates with anti-cyclin E antibody were assayed for histone H1 kinase activity.

of p27<sup>DAP</sup>, inhibits the activity of cyclin E-cdk2, leading to a block of the G<sub>1</sub>-S transition in vertebrate cells (Polyak *et al.*, 1994a). Accordingly, we tested the possibility that *Cdh1*-deficient cells abrogate G<sub>1</sub> arrest induced by the expression of p27<sup>Kip1</sup>. (In the subsequent experiments, both *Cdh1*<sup>-/-</sup> clones behaved identically. Therefore, the results obtained from clone 1 are reported below.) We employed rapamycin, which is known to activate p27<sup>Kip1</sup> expression (Nourse *et al.*, 1994), to induce G<sub>1</sub> arrest in DT40 cells. The p27<sup>Kip1</sup> protein levels were up-regulated in both wild-type and *Cdh1*<sup>-/-</sup> DT40 cells after 72 h of rapamycin treatment (Figure 5A). FACS analysis revealed that rapamycin treatment for 72 h induced G<sub>1</sub> arrest in wild-type cells (Figure 5B and C). In contrast, *Cdh1*<sup>-/-</sup> DT40 cells showed a significant decrease in the G<sub>1</sub> fraction at 72 h of rapamycin treatment, and a corresponding increase in the number of cells with S phase DNA content (Figure 5B and C). While pRb was not phosphorylated in wild-type cells treated with rapamycin, *Cdh1*<sup>-/-</sup> cells dominantly expressed the phosphorylated form (Figure 5A). In addition, *Cdh1*<sup>-/-</sup> cells expressing the human *Cdh1* transgene arrested in G<sub>1</sub> in the presence of rapamycin, similarly to wild-type cells (Figure 5B). All these findings indicate that loss of *Cdh1* results in abrogation of rapamycin-induced G<sub>1</sub> arrest. Furthermore, *Cdh1*<sup>-/-</sup> cells treated with olomoucine, which is a specific cdk2 kinase

inhibitor, were induced to undergo G<sub>1</sub> arrest in the presence of rapamycin (Figure 5C). This result suggests that the abrogation of G<sub>1</sub> arrest in *Cdh1*-deficient cells is caused by unscheduled activation of cdk2 kinase.

The expression of p27<sup>Kip1</sup> induces G<sub>1</sub> arrest by inhibiting the activity of the cyclin E-cdk2 complex, which is essential for initiation of DNA replication (Polyak *et al.*, 1994b). It has also been shown that p27<sup>Kip1</sup> interacts with the cyclin A-cdk2 complex and inhibits its kinase activity (Blain *et al.*, 1997). Therefore, it can be postulated that p27<sup>Kip1</sup> is sequestered by the cyclin A-cdk2 complex ectopically accumulated during the G<sub>1</sub> phase in *Cdh1*<sup>-/-</sup> cells, resulting in activation of the cyclin E-cdk2 complex and leading to abrogation of the rapamycin-induced G<sub>1</sub> arrest. To investigate this, cyclin E and cyclin A immunoprecipitated with p27<sup>Kip1</sup> were examined in wild-type and *Cdh1*<sup>-/-</sup> cells that were treated with rapamycin for 72 h. While a large amount of cyclin E was associated with p27<sup>Kip1</sup> in wild-type cells, cyclin E was reduced in p27<sup>Kip1</sup> immunoprecipitates in *Cdh1*<sup>-/-</sup> cells (Figure 5D). Conversely, association between cyclin A and p27<sup>Kip1</sup> was markedly increased in *Cdh1*<sup>-/-</sup> cells. Furthermore, the cyclin E-associated kinase activity was significantly higher in the lysate derived from *Cdh1*<sup>-/-</sup> cells than in that from wild-type cells (Figure 5D). These findings suggest that the cyclin E-cdk2 complex dissociated from

p27<sup>Kip1</sup>, which is sequestered by ectopically accumulated cyclin A-cdk2 complex, leads to abrogation of G<sub>1</sub> arrest in *Cdh1*<sup>-/-</sup> cells.

### Loss of Cdh1 causes premature entry into mitosis after DNA damage


In the normal cell cycle, cyclin A and cyclin B begin to accumulate from early S phase and G<sub>2</sub> phase, respectively. We tested whether loss of Cdh1 affected levels of mitotic cyclins in S and G<sub>2</sub> and cell cycle progression from S to mitotic entry. Wild-type or *Cdh1*<sup>-/-</sup> DT40 cells were synchronized in early S phase by an aphidicolin block. At different times after release from the S block, the protein levels of cyclin A and cyclin B and the mitotic index were determined. Immunoblot analyses showed that the expression of mitotic cyclins from S through G<sub>2</sub> and early M phases was comparable in wild-type and *Cdh1*<sup>-/-</sup> cells (data not shown). Furthermore, the rate of mitotic entry of *Cdh1*<sup>-/-</sup> cells after release from S block was similar to that of wild-type cells (Figure 6A). These data suggest that Cdh1 deficiency does not impair transition from S phase to mitotic entry in normal cell cycle progression.

Although our original goal in this work was to understand the involvement of Cdh1 in normal cell cycle progression, our results identify a new role for Cdh1 in cell cycle checkpoints responsive to damaged DNA. Cells released from early S phase block were exposed to 10 Gy of X radiation at mid-S phase, and the cell cycle progression of wild-type and *Cdh1*<sup>-/-</sup> cells after irradiation was assessed by counting the rate of mitotic entry and by FACS analysis of DNA. Morphological examination revealed that both genotypes entered mitosis within 4 h after release from S block without irradiation (Figure 6A). Following treatment with 10 Gy of X radiation, the vast majority of wild-type cells appeared to arrest in the G<sub>2</sub> phase until 6 h after irradiation, suggesting that wild-type cells have the damaged DNA-induced G<sub>2</sub> checkpoint function (Figure 6B, upper panel). However, substantially more *Cdh1*<sup>-/-</sup> cells entered mitosis relative to wild-type cells at 5 h after irradiation, indicative of a defect in the G<sub>2</sub> checkpoint. Moreover, in FACS analysis, *Cdh1*<sup>-/-</sup> cells showed a relative decrease in the G<sub>2</sub> fraction as early as 8 h after irradiation and a corresponding increase in the number of cells having sub-G<sub>1</sub> DNA content, which is characteristic of dead cells (Figure 6C). These findings suggest that the massive cell death of Cdh1-deficient cells after irradiation was due to premature entry into mitosis with DNA damage and, thereby, that Cdh1 plays a crucial role in the damaged DNA-induced G<sub>2</sub> checkpoint.

DNA strand damage caused by UV-irradiation also activates the G<sub>2</sub> checkpoint, but molecular mechanisms involved in regulating G<sub>2</sub> delay after UV-irradiation are different from those after X-irradiation (Bulavin *et al.*, 2001). In contrast to X-irradiation, UV-irradiation induced a G<sub>2</sub> delay in both genotypes (Figure 6B, lower panel), suggesting that Cdh1 deficiency has no effect on the UV-induced G<sub>2</sub> checkpoint.


### DNA damage induces activation of Cdh1-APC

The activity of APC is largely dependent on its interaction with Cdc20 or Cdh1 (Kramer *et al.*, 2000). The phosphorylation of Cdh1 is known to prevent binding to and activation of the APC. Hct1, a budding yeast homolog of



**Fig. 6.** *Cdh1*-deficient cells are unable to maintain G<sub>2</sub> arrest after X-irradiation. (A) Cells were synchronized at early S phase by an aphidicolin block. Mitotic indices of wild-type cells (filled circles) and *Cdh1*<sup>-/-</sup> cells (filled triangles) were determined by counting cells with mitotic spindles at the indicated times after the release from aphidicolin block. Mitotic spindles were determined by staining cells with an anti- $\alpha$ -tubulin antibody. (B) Cells were treated with 10 Gy of X radiation (upper panel) or 5 J/m<sup>2</sup> of UV radiation (lower panel) 1 h after the release from aphidicolin block. Mitotic indices of wild-type cells (filled circles) and *Cdh1*<sup>-/-</sup> cells (filled triangles) were determined by the same method as described in (A) at the indicated times. (C) Wild-type cells and *Cdh1*<sup>-/-</sup> cells were synchronized at early S phase and exposed to 10 Gy of X radiation 1 h after the release from the block. At the indicated time points after the release, cells were harvested and analyzed by FACS.

Cdh1, was shown to be inactivated through phosphorylation by maturation-promoting factor (MPF) and activated through dephosphorylation by Cdc14 from late mitosis to the end of the G<sub>1</sub> phase (Visintin *et al.*, 1998; Jaspersen *et al.*, 1999). Moreover, it has been suggested that interaction of Cdh1 and APC (active Cdh1-APC) is maintained until late in the G<sub>1</sub> phase and diminished by the phosphorylation of Cdh1 with cdk2 from S phase in mammalian cells (Lukas *et al.*, 1999; Kramer *et al.*, 2000).



**Fig. 7.** Activation of the Cdh1–APC complex after X-irradiation-induced DNA damage. **(A)** *Cdh1*<sup>−/−</sup> cells expressing HA-tagged human Cdh1 were synchronized in early S phase by aphidicolin treatment and treated with 10 Gy of X radiation. The cell extracts harvested at 4 h after the release were immunoprecipitated with antibodies against HA. Cdc27, a component of the APC complex contained in total cell lysates was determined by immunoblotting (left panel). The relative amount of Cdc27, precipitated with the HA-human Cdh1, was determined by immunoblotting (right panel). **(B)** HeLa cells were synchronized at the beginning of S phase by the double thymidine block and treated with 10 Gy of X radiation 3 h after the release from S block. Rat1 fibroblasts were synchronized at early S phase by aphidicolin treatment and treated with 10 Gy of X radiation 1 h after the release from aphidicolin block. The cell extracts harvested at 8 h (HeLa) or 4 h (Rat1) after the release were immunoprecipitated with an antibody against Cdc27. Cdc27 and Cdh1 co-immunoprecipitated with Cdc27 antibody were detected by immunoblotting with their specific antibodies. **(C)** *In vitro* ubiquitination assay. HeLa cells synchronized at G<sub>2</sub> phase were treated with or without X-irradiation as described in (B). APC immunoprecipitated with anti-Cdc27 antibody from the cell lysates was subjected to the *in vitro* ubiquitination assay as described in Materials and methods. The reaction was terminated at the times indicated. His-Cdc20 (arrow) was used as a substrate. ‘Ub-Cdc20’ indicates ubiquitylated Cdc20. **(D)** Ubiquitylation of Cdh1-associated complex after X-irradiation. HeLa cells transfected with ubiquitin and HA-Cdh1 were treated with 10 Gy of X radiation 3 h after the release from S block and immunoprecipitated with anti-HA antibody. Ubiquitylated proteins precipitated with HA-tagged Cdh1 were detected by immunoblotting with an anti-ubiquitin antibody. **(E)** The amounts of mitotic cyclins in wild-type and *Cdh1*<sup>−/−</sup> DT40 cells. Cells were synchronized by aphidicolin treatment for 10 h, irradiated with 10 Gy 1 h after the release and analyzed by immunoblotting with anti-cyclin A and B antibodies. The time indicated was that after the release. The corresponding Ku70 levels are shown as a loading control.

These previous observations indicate that Cdh1–APC activity in normal cells is down-regulated by the dissociation of Cdh1 from the APC during S phase through to mitotic entry in the normal cell cycle. Based on our findings obtained using *Cdh1*<sup>−/−</sup> DT40 cells, we investigated whether APC is activated in the G<sub>2</sub> phase through interaction with Cdh1 in response to DNA damage. *Cdh1*<sup>−/−</sup> cells expressing the human *Cdh1* transgene were synchronized in early S phase by treatment with aphidicolin. The cells released from early S phase block were exposed to X-irradiation, and interaction between Cdh1 and APC was investigated. In the cells not treated with X-irradiation, Cdh1 had little association with Cdc27, a component of the APC complex, during G<sub>2</sub> phase (Figure 7A), which is consistent with findings reported previously (Kramer *et al.*, 2000). In contrast, when cells were exposed

to X-irradiation at 1 h after release from S block, Cdh1 was induced to interact with Cdc27 in the G<sub>2</sub> phase (Figure 7A). Interaction between Cdh1 and the APC complex induced by DNA damage was observed not only in DT40 cells but also in both rodent fibroblast (Rat1 cell) and a human cancer cell line (HeLa cell) (Figure 7B).

Having determined the complex formed by APC and Cdh1 after DNA damage, we asked whether the Cdh1–APC complex becomes catalytically active in response to DNA damage. First, we performed an *in vitro* ubiquitylation assay using human Cdc20 as substrate. Human Cdc20 contains a KEN box, which was shown to be the Cdh1-specific targeting motif (Pfleger and Kirschner, 2000) and, thereby, is considered to be a specific substrate for Cdh1–APC. APC immunoprecipitated with anti-Cdc27 antibody from cells in normal G<sub>2</sub> phase showed no activity to ubiquitylate human Cdc20 (Figure 7C, lanes 5–8), which is consistent with results reported previously (Kramer *et al.*, 2000). In contrast, APC purified from cells arrested in the G<sub>2</sub> phase after X-irradiation ubiquitylated human Cdc20 in a time-dependent manner (Figure 7C, lane 1–4), suggesting that Cdh1–APC becomes catalytically active by DNA damage induced by X-irradiation. Furthermore, we attempted to investigate the *in vivo* ubiquitylation of the Cdh1–APC complex after X-irradiation in the G<sub>2</sub> phase. HeLa cells stably expressing human ubiquitin were established and used to examine the ubiquitylation of the Cdh1-associated complex. Ubiquitylation of the complex immunoprecipitated with hemagglutinin (HA)-tagged Cdh1 was very low in cells in the G<sub>2</sub> phase without DNA damage (Figure 7D, left lane). However, Cdh1-associated complex in X-irradiated cells in the G<sub>2</sub> phase showed significantly increased ubiquitylation (Figure 7D, right lane). All these findings suggest that Cdh1–APC is activated at the X-irradiation-induced G<sub>2</sub> checkpoint.

Our findings indicate the possibility that activation of Cdh1–APC by DNA damage may induce degradation of regulators for G<sub>2</sub>–M transition, resulting in G<sub>2</sub> arrest. In HeLa and other cells, it is known that the expression of cyclin B is down-regulated in S and G<sub>2</sub> phase in response to DNA damage (Muschel *et al.*, 1993). To investigate whether abrogation of the damaged DNA-induced G<sub>2</sub> checkpoint in *Cdh1*<sup>−/−</sup> cells is due to an inability to degrade mitotic cyclins, the protein levels of mitotic cyclins after X-irradiation were examined. Immunoblot analyses showed that the levels of mitotic cyclins did not change significantly but remained similarly stable in both wild-type and *Cdh1*<sup>−/−</sup> cells (Figure 7E). These data suggest that the degradation of mitotic cyclins mediated by the Cdh1–APC complex plays little role in the G<sub>2</sub> checkpoint after DNA damage.

## Discussion

### Role of Cdh1 in the mitotic phase

In the present study, we have generated *Cdh1*-deficient cells using DT40 chicken B lymphocytes. *Cdh1*<sup>−/−</sup> DT40 cells appeared to be exiting mitosis and proliferating normally despite the fact that expression of cyclin A and cyclin B in these cells in M and G<sub>1</sub> phases was significantly elevated. These findings suggest that Cdh1 plays a major role in proteolysis of mitotic cyclins from the

M to G<sub>1</sub> phases but is dispensable for viability and proliferation of higher vertebrate cells, which is similar to observations in yeast and *Drosophila* (Schwab *et al.*, 1997; Sigrist and Lehner, 1997). In higher vertebrate cells, cyclin B destruction has been believed to be required for exit from mitosis. However, recent observation has clearly demonstrated that mammalian cells overexpressing cyclin B1 are capable of exiting mitosis (Jin *et al.*, 1998), which appears consistent with our result.

Our results show that mitotic cyclins accumulate significantly but are partially degraded at the end of mitosis in *Cdh1*<sup>-/-</sup> cells, suggesting that not only Cdh1 but also another molecule, such as Cdc20, is involved in the proteolysis of mitotic cyclins in the mitotic phase. In budding yeast, Hct1/Cdh1 and Cdc20 have been shown to target some common molecules, and the main difference between them is the time during the cell cycle when each is active (Yeong *et al.*, 2000). Furthermore, Cdc20-APC can only be activated under conditions in which Hct1/Cdh1-APC is inactive, and this dependency helps to ensure that the events of mitosis occur in the proper sequence (Lim *et al.*, 1998; Visintin *et al.*, 1998; Shirayama *et al.*, 1999; Yeong *et al.*, 2000). Therefore, collectively, these previous data suggest that Cdc20 and Hct1/Cdh1 target distinct, but overlapping sets of proteins for degradation in crucial mitotic events, such as separation of sister chromatids and exit from mitosis. It was found recently that in early *Xenopus* embryos, Cdh1 is not expressed (Lorca *et al.*, 1998), indicating that Cdh1 is not required for cyclin oscillations in early embryonic cell cycles. Similarly, Cdh1 is not expressed in early fly embryos, where Cdc20 is required for cyclin destruction (Sigrist and Lehner, 1997). Additionally, vertebrate Cdc20-APC and Cdh1-APC both ubiquitylate mitotic cyclins *in vitro* (Fang *et al.*, 1998). Thus, it is reasonable to speculate that Cdc20 promotes not only the initiation of anaphase but also the partial destruction of mitotic cyclins, which is sufficient for exit from mitosis, in *Cdh1*<sup>-/-</sup> DT40 cells. Our observations suggest that proteolysis of mitotic cyclins is regulated by two steps, mediated by Cdc20 and Cdh1, in higher vertebrate cells.

Although Cdh1 is dispensable for viability of DT40 cells, the length of time between anaphase and the end of mitosis was found to be prolonged in *Cdh1*<sup>-/-</sup> DT40 cells. This result suggests that Cdh1-APC regulates the progression of late mitosis despite the fact that it is not essential for exiting mitosis.

#### **Involvement of Cdh1 in G<sub>1</sub>-S transition**

In cultured human cells, ectopic overexpression of cyclin A can drive premature entry into S phase and causes a decrease in the percentage of cells in G<sub>1</sub> (Resnitzky *et al.*, 1995). These results demonstrate that the expression of cyclin A is rate limiting for the G<sub>1</sub>-S transition. However, our observations showed that *Cdh1*<sup>-/-</sup> DT40 cells have a normal G<sub>1</sub> phase and do not enter S phase prematurely despite the high expression of both cyclin A and cyclin B. These findings suggest that the accumulation of mitotic cyclins due to loss of Cdh1 does not affect the duration of the G<sub>1</sub> phase in normal exponential conditions. This discrepancy may be explained by a difference in the expression levels of cyclin A. The level of cyclin A induced by the exogenous expression system in the study

of Resnitzky *et al.* (1995) appears to be much higher than physiological levels. Thus, it is possible that the levels of mitotic cyclins accumulated at G<sub>1</sub> phase in Cdh1-deficient cells are not enough to induce premature entry into S phase.

In *fzr*-deficient *Drosophila* embryos, epidermal cells progress through an extra division cycle without stopping in G<sub>1</sub> after terminal mitosis. This defect is believed to be caused by failure to decrease mitotic cyclins (Sigrist and Lehner, 1997). Furthermore, *srw1*-mutant fission yeasts also do not arrest at G<sub>1</sub> under conditions of nitrogen starvation (Yamaguchi *et al.*, 1997). Similarly, we found that *Cdh1*<sup>-/-</sup> DT40 cells abrogate the G<sub>1</sub> arrest induced by rapamycin, which is an activator of p27<sup>Kip1</sup>, following entry into S phase. p27<sup>Kip1</sup> is known to induce G<sub>1</sub> arrest by inhibiting the activity of the cyclin E-cdk2 complex. p27<sup>Kip1</sup> has also been shown to interact with cyclin A-cdk2. Since the induction of p27<sup>Kip1</sup> expression by rapamycin was similar in both wild-type and *Cdh1*<sup>-/-</sup> DT40 cells (Figure 5A), one mechanistic explanation as to how inactivation of Cdh1 can cause an abrogation of G<sub>1</sub> cell cycle arrest is by sequestration of p27<sup>Kip1</sup> by accumulated cyclin A-cdk2 complex to activate cyclin E-cdk2. Four lines of evidence presented here support this hypothesis. First, inhibition of cdk2 kinase activity by treatment with olomoucine led *Cdh1*<sup>-/-</sup> cells to arrest at the G<sub>1</sub> phase in the presence of rapamycin (Figure 5C). Secondly, the amounts of cyclin E associated with p27<sup>Kip1</sup> were decreased in *Cdh1*<sup>-/-</sup> cells. Thirdly, p27<sup>Kip1</sup> interacted predominantly with ectopically accumulated cyclin A in *Cdh1*<sup>-/-</sup> cells. Finally, the level of cyclin E-associated kinase activity was dramatically elevated in *Cdh1*<sup>-/-</sup> cells (Figure 5D). In fission yeast, cdk1 activated by B-type cyclin can promote G<sub>1</sub>-S progression in the absence of G<sub>1</sub> cyclin (Fisher and Nurse, 1996). Therefore, the possibility cannot be ruled out that cdk1 activated with ectopically accumulated cyclin B may promote G<sub>1</sub>-S transition in rapamycin-treated *Cdh1*<sup>-/-</sup> cells. It is also possible that high levels of cyclin A promote transition of *Cdh1*<sup>-/-</sup> cells from G<sub>1</sub> to S phase. In any case, our findings suggest that activation of Cdh1 plays a crucial role in establishment of G<sub>1</sub> arrest by cooperating with inhibitors of G<sub>1</sub> cyclin-dependent kinases.

#### **Activation of Cdh1-APC in the DNA damage-induced G<sub>2</sub> checkpoint**

Recent reports have shown that Cdh1-APC is inactivated from S phase until the mid-mitotic phase through phosphorylation by cyclin A-cdk2 or cyclin B-cdk1 in mammalian cells (Lukas *et al.*, 1999). These data indicate that Cdh1-APC is not required for progression of the cell cycle from S phase to mitotic entry, which is consistent with our finding that Cdh1 deficiency does not affect the cell cycle progression from S phase to the mitotic phase in physiological conditions. However, we found that *Cdh1*<sup>-/-</sup> cells failed to maintain X-irradiation-induced arrest in the G<sub>2</sub> phase of the cell cycle. This finding strongly suggests that the activation of Cdh1-APC plays a role in DNA damage-induced G<sub>2</sub> checkpoint function. In fact, we demonstrate here that X-irradiation induces interaction of Cdh1 with APC in the G<sub>2</sub> phase (Figure 7A and B) and consequently activates the Cdh1-APC (Figure 7C and D).

These findings indicate that Cdh1–APC is activated at G<sub>2</sub> by X-irradiation-induced DNA damage.

How can Cdh1–APC induce G<sub>2</sub> arrest in response to DNA damage? One obvious possibility is that Cdh1–APC targets regulators for G<sub>2</sub>–M transition. However, our findings showed that the levels of mitotic cyclins in *Cdh1*<sup>−/−</sup> cells after DNA damage were similar to those in wild-type cells (Figure 7E). These data imply that cyclin A and cyclin B cannot be substrates for Cdh1–APC when it is activated irregularly by DNA damage at G<sub>2</sub>. Recent reports have demonstrated that Cdc20 strictly recognizes a substrate with a well-defined D-box, whereas Cdh1–APC recognizes both D-box and non-D-box substrates (Pfleger and Kirschner, 2000) for destruction. Therefore, the regulation of the interaction between Cdh1–APC and those diverse substrates may be dependent on the cell cycle phases and events. It seems likely that critical molecules for promoting the G<sub>2</sub>–M transition, besides mitotic cyclins, are potential substrates of activated Cdh1–APC in the DNA damage checkpoint and that the degradation of those substrates by the activated Cdh1–APC induces G<sub>2</sub> arrest.

We demonstrate that UV radiation induced G<sub>2</sub> delay not only in wild-type cells but also in *Cdh1*<sup>−/−</sup> cells (Figure 6B), suggesting that Cdh1 deficiency has no effect on the UV-induced G<sub>2</sub> checkpoint. Recently, it has been reported that molecular mechanisms regulating UV-induced G<sub>2</sub> delay are distinct from those induced by X radiation (Bulavin *et al.*, 2001). Therefore, this result shows that Cdh1 is involved in the X-irradiation-induced G<sub>2</sub> checkpoint pathway but not in the UV-induced G<sub>2</sub> checkpoint pathway.

### Involvement of Cdh1–APC in cancers

The maintenance of genomic integrity after DNA damage depends on the coordinated action of the DNA repair and checkpoint systems. The failure of a checkpoint leads to genomic instability and predisposition to cancer (Lengauer *et al.*, 1998). Since our findings suggest that activation of Cdh1–APC is required for both cdk inhibitor-dependent G<sub>1</sub> arrest and DNA damage-induced G<sub>2</sub> arrest, it is conceivable that abnormal regulation of Cdh1 activation may involve failure in normal cell cycle progression, leading to genetic and chromosomal instabilities, which result in development of malignant tumors. Investigation of this possibility is currently underway using various cancer cells.

Our findings also have potential relevance for the treatment of cancer. Abrogation of the DNA damage-induced G<sub>2</sub> checkpoint sensitizes cells to genotoxic stress. This suggests that a specific inhibitor of DNA damage-induced Cdh1 activation could make radiotherapy and/or chemotherapy more effective.

## Materials and methods

### Cell culture

DT40 cells were cultured in RPMI1640 medium supplemented with 10<sup>−5</sup> M β-mercaptoethanol, penicillin/streptomycin, 10% fetal calf serum and 1% chicken serum (Sigma) at 37°C. Rat1 and HeLa cells were cultured in Dulbecco's modified Eagle's medium (DMEM)-F12 supplemented with penicillin/streptomycin and 10% fetal calf serum.

### Plasmid constructs

Chicken *Cdh1* cDNA was amplified by RT-PCR using mRNA extracted from DT40 cells with primers for human *Cdh1*. Using this cDNA, ~9 kb of the chicken genomic *cdh1* locus was isolated from DT40 genomic DNA using long-range PCR. Chicken *Cdh1* disruption constructs, *Cdh1*-Bsr (blasticidin) and *Cdh1*-His (histidinol), were made by replacing ~1 kb of the genomic sequence of *Cdh1* with Bsr and His selection marker cassettes (Figure 1A).

### Gene targeting

For gene targeting of the chicken *Cdh1* locus, DT40 cells (10<sup>7</sup>) were suspended in 0.5 ml of phosphate-buffered saline (PBS) containing 30 μg of linearized targeting vector for each transfection and electroporated with a Gene Pulser apparatus (BTX) at 210 V and 475 μF. Following electroporation, cells were transferred into 20 ml of fresh medium and incubated for 24 h. Cells were then resuspended in 80 ml of medium containing 30 μg/ml blasticidin-S (Calbiochem) or 1 mg/ml histidinol (Sigma) and divided into four 96-well plates. After 7–10 days, drug-resistant colonies were transferred to 24-well plates. Genomic DNA was extracted from each expanded clone, and successful targeted recombination was identified by Southern blot and PCR analyses. To generate *Cdh1*<sup>−/−</sup> cells expressing the human *Cdh1* transgene, we transfected cells with the pUHG plasmid containing human *Cdh1* and selected stable transformants with 2.5 mg/ml hygromycin (Calbiochem).

### Genomic PCR and RT-PCR

To evaluate the targeted allele, genomic DNA from DT40 cells was amplified using the three sets of primers (p2–p4, p1–p3 and p1–p5) illustrated in Figure 1(A). Genomic DNA was prepared using InstaGene Matrix (Bio-Rad). mRNA was isolated using a Micro-FastTrack 2.0 kit (Invitrogen) and reverse-transcribed using the Superscript cDNA synthesis system as described by the suppliers (Gibco-BRL). Full-length chicken *Cdh1* cDNA was amplified by PCR with 35 cycles of 94°C (1 min), 60°C (1 min) and 72°C (1 min). Primers for the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) were used along with the primers for the amplification of *Cdh1* cDNA.

### Antibodies

Proteins were detected by anti-chicken cyclin A antibody (Transduction Laboratories), anti-chicken cyclin B2 antibody (Gallant and Nigg, 1992), anti-cyclin E antibody (Santa Cruz), anti-Rb antibody (Transduction Laboratories), anti-ubiquitin antibody (Sigma), anti-chicken Ku70 antibody (Takata *et al.*, 1998) and anti-Cdh1 antibody (Wang *et al.*, 2000).

### Cell cycle analysis

To analyze the intracellular DNA content, cells were fixed in 70% methanol at −20°C for several hours. Cells were centrifuged at 2000 r.p.m. and resuspended in PBS containing RNase A (Sigma) at 0.1 mg/ml. Samples were incubated at 37°C for 15 min, and propidium iodide (Sigma) was added to a final concentration of 25 μg/ml. Samples were processed by a FACScan (Becton Dickinson) using Cell Quest software (Becton Dickinson). For determination of the bromodeoxyuridine (BrdU) incorporation, cells were labeled for 10 min with 20 μM BrdU (Amersham). They were harvested and fixed in 70% methanol at −20°C for several hours. Then, cells were stained with an anti-BrdU antibody as described previously (Sonoda *et al.*, 1998).

### Cell synchronization

In DT40 cells, to synchronize cells at the G<sub>1</sub>, early S phase or metaphase, cells were cultured in the presence of 100 nM rapamycin (Calbiochem) for 72 h, 1 μg/ml aphidicolin (Wako) for 10 h or 0.5 μg/ml nocodazole (Sigma) for 10 h, respectively. Rat1 cells were synchronized at early S phase by 1 μg/ml aphidicolin treatment for 12 h. HeLa cells were synchronized at the beginning of S phase by means of a double thymidine/aphidicolin block. Briefly, HeLa cells were incubated with 2.0 mM thymidine (Sigma) for 24 h, released for 8 h and then treated with 1 μg/ml aphidicolin for a further 16 h. Cells were exposed to 10 Gy of X-rays at 1 h (DT40 and Rat1) or 3 h (HeLa) after release from S block.

### Detection of cells at mitosis

Cells with mitotic condensed chromatin were visualized by staining with aceto-orcein (Merck) in 60% acetic acid (Hirota *et al.*, 2000). Cells at anaphase and telophase are easily identified by aceto-orcein staining. To avoid the morphological confusion between mitotic cells and apoptotic cells in the X- and UV-irradiation experiments, mitotic indices were determined by counting cells with mitotic spindles. To detect the mitotic



spindles, DT40 cells were fixed with 100% methanol for 10 min, washed with PBS twice and incubated in a blocking buffer (1% bovine serum albumin in PBS) for 1 h at room temperature. The cells were incubated with the monoclonal antibody against  $\alpha$ -tubulin (Sigma) for 20 h at 4°C, washed with PBS and incubated with fluorescein isothiocyanate (FITC)-conjugated anti-mouse IgG (Biosource) for 4 h at room temperature.

The proportion of cells in the mitotic phase was also determined by FACS analysis using anti-MPM-2 antibody (Upstate Biotechnology). Briefly, cells were harvested and fixed in 70% methanol at -20°C for several hours. Fixed cells were stained for 1 h at room temperature with anti-MPM-2 antibody, washed three times in PBS and stained with FITC-conjugated anti-mouse IgG (Biosource). Stained cells were analyzed with FACScan using Cell Quest software.

### Immunoprecipitation

Cells were washed with PBS and used immediately, or were frozen in liquid nitrogen and stored at -80°C. The cells were then lysed in 0.5% Triton X-100 lysis buffer (20 mM Tris-HCl pH 7.7, 100 mM KCl, 50 mM sucrose, 0.1 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 0.5% Triton X-100, 20 mM  $\beta$ -glycerophosphate, 1 mM Na<sub>2</sub>VO<sub>4</sub> and a cocktail of protease inhibitors). The extracts were centrifuged at 14 000 r.p.m. for 15 min at 4°C, and the supernatants were used for immunoprecipitation. Aliquots of supernatants were incubated for 2 h at 4°C with a monoclonal anti-p27<sup>Kip1</sup> antibody (Transduction Laboratories), anti-Cdc27 antibody (Santa Cruz) and anti-HA antibody (Boehringer Mannheim), respectively. Cells were incubated for another 2 h after addition of protein G plus protein A-agarose beads (Oncogene Science). The washed immunoprecipitants and the supernatant were collected for western blotting.

### Histone H1 kinase assay

Cells were washed with PBS twice and suspended in 120  $\mu$ l of lysis buffer (20 mM Tris-HCl pH 7.5, 10 mM EDTA, 100 mM NaCl, 1% Triton X-100, 1 mM NaF, 1 mM  $\beta$ -glycerophosphate and a cocktail of protease inhibitors). A 100  $\mu$ l aliquot of lysates and 5  $\mu$ l of an anti-cyclin E antibody were mixed and incubated for 1 h at 4°C. Then, a 20  $\mu$ l aliquot of protein G plus protein A-agarose beads was added. After gentle agitation for 30 min at 4°C, beads were washed four times in lysis buffer, the second wash containing 1 M NaCl, and twice in kinase buffer [25 mM MOPS pH 7.2, 15 mM MgCl<sub>2</sub>, 5 mM EDTA, 1 mM dithiothreitol (DTT), 60 mM  $\beta$ -glycerophosphate, 0.1 mM sodium orthovanadate and a cocktail of protease inhibitors]. Pelleted beads were mixed with an equal volume of a reaction mix containing Triton X-100 (1%), [ $\gamma$ -<sup>32</sup>P]ATP and histone H1 (1 mg/ml) and incubated for 15 min at 30°C. The reaction was chilled and stopped by addition of a sample buffer. The samples were loaded on an SDS-polyacrylamide gel and visualized by autoradiography.

### In vitro ubiquitination assay

The N-terminal half of human Cdc20 cDNA encoding amino acid residues 1-250 was inserted into pET23d and expressed in NovaBlue (DE3) (Novagene). The His-tagged recombinant Cdc20 protein was purified and biotinylated (Pierce). The *in vitro* ubiquitination assay was carried out as described previously (Kotani *et al.*, 1998, 1999). In brief, synchronized HeLa cells were treated with or without X-irradiation at the G<sub>2</sub> phase, and the cell extracts harvested 8 h after the release were immunoprecipitated with anti-Cdc27 antibody. Immunoprecipitants were incubated with 2  $\mu$ g of His-Cdc20 in 30  $\mu$ l of 5 mM Tris pH 7.6, 0.5 mM MgCl<sub>2</sub>, 2 mM ATP, 2 mM DTT, 2 mM creatinine phosphate, 1  $\mu$ g/ml creatine, phosphokinase, 0.2 mg/ml bovine ubiquitin (Sigma), 40  $\mu$ g/ml mouse recombinant E1 and 50  $\mu$ g/ml human recombinant hE2-C. After the reaction, His-Cdc20 was purified using ProBond resin, subjected to SDS-PAGE and transferred onto a nitrocellulose membrane followed by detection with streptavidin-horseradish peroxidase.

### In vivo ubiquitylation of Cdh1-associated complex

HeLa cells were transfected with myc-tagged ubiquitin expression plasmid (pcDNA3/myc-Ub), and neomycin-resistant clones were isolated and cultured in the presence of 1 mg/ml geneticin (Gibco-BRL). To synchronize the myc-ubiquitin-expressing HeLa cells at early S phase, asynchronously growing cells were treated with 2 mM thymidine for 16 h. Cells were then released from the block by changing to complete growth medium containing 24 mM each of thymidine and deoxycytidine. At 6 h after the release, cells were transfected with *Cdh1*/pCGN-HA using FuGENE 6 (Roche) reagent. After 2 h, thymidine was added to the medium to a final concentration of 2 mM and cells were cultured for another 16 h. Before harvest at 8 h after the release, 10 mM MG132 (Calbiochem) was added to the medium and incubated for 1 h. An immunoprecipitation analysis with anti-HA antibody was performed as

described above. The samples were subjected to SDS-PAGE followed by immunoblot analysis using anti-ubiquitin antibody (Sigma).

## Acknowledgements

We thank Dr A. Venkitaraman for helpful discussions and critical reading of the manuscript, Dr Q. Hu for providing the pCGN plasmids, Drs E. Nigg and J. Braun for providing the anti-cyclin B2 and Cdh1 antibodies, respectively, Dr J. Moon for editorial assistance, Drs K. Yonezawa, K. Todokoro, T. Hirota, T. Morisaki and T. Marumoto for helpful discussions, and T. Arino and Y. Fukushima for secretarial assistance. This work was supported by a grant for cancer research from the Ministry of Education, Science and Culture of Japan (H.S.).

## References

- Agami, R. and Bernards, R. (2000) Distinct initiation and maintenance mechanisms cooperate to induce G<sub>1</sub> cell cycle arrest in response to DNA damage. *Cell*, **102**, 55-66.
- Blain, S.W., Montalvo, E. and Massague, J. (1997) Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27<sup>Kip1</sup> with cyclin A-Cdk2 and cyclin D2-Cdk4. *J. Biol. Chem.*, **272**, 25863-25872.
- Bulavin, D.V., Higashimoto, Y., Popoff, I.J., Gaarde, W.A., Basur, V., Potapova, O., Apella, E. and Fornace, A.J. (2001) Initiation of a G<sub>2</sub>/M checkpoint after ultraviolet radiation requires p38 kinase. *Nature*, **411**, 102-107.
- Cohen-Fix, O. and Koshland, D. (1997) The metaphase-to-anaphase transition: avoiding a mid-life crisis. *Curr. Opin. Cell Biol.*, **9**, 800-806.
- Davis, F.M., Tsao, T.Y., Fowler, S.K. and Rao, P.N. (1983) Monoclonal antibodies to mitotic cells. *Proc. Natl Acad. Sci. USA*, **80**, 2926-2930.
- Du, W. and Dyson, N. (1999) The role of RBF in the introduction of G<sub>1</sub> regulation during *Drosophila* embryogenesis. *EMBO J.*, **18**, 916-925.
- Fang, G., Yu, H. and Kirschner, M.W. (1998) Direct binding of CDC20 protein family members activates the anaphase-promoting complex in mitosis and G<sub>1</sub>. *Mol. Cell*, **2**, 163-171.
- Fisher, D.L. and Nurse, P. (1996) A single fission yeast mitotic cyclin B p34cdc2 kinase promotes both S-phase and mitosis in the absence of G<sub>1</sub> cyclins. *EMBO J.*, **15**, 850-860.
- Funabiki, H., Yamano, H., Kumada, K., Nagao, K., Hunt, T. and Yanagida, M. (1996) Cut2 proteolysis required for sister-chromatid separation in fission yeast. *Nature*, **381**, 438-441.
- Gallant, P. and Nigg, E.A. (1992) Cyclin B2 undergoes cell cycle-dependent nuclear translocation and, when expressed as a non-destructible mutant, causes mitotic arrest in HeLa cells. *J. Cell Biol.*, **117**, 213-224.
- Hirota, T. *et al.* (2000) Zyxin, a regulator of actin filament assembly, targets the mitotic apparatus by interacting with h-warts/LATS1 tumor suppressor. *J. Cell Biol.*, **149**, 1073-1086.
- Jaspersen, S.L., Charles, J.F. and Morgan, D.O. (1999) Inhibitory phosphorylation of the APC regulator Hct1 is controlled by the kinase Cdc28 and the phosphatase Cdc14. *Curr. Biol.*, **9**, 227-236.
- Jin, P., Hardy, S. and Morgan, D.O. (1998) Nuclear localization of cyclin B1 controls mitotic entry after DNA damage. *J. Cell Biol.*, **141**, 875-885.
- Juang, Y.L., Huang, J., Peters, J.M., McLaughlin, M.E., Tai, C.Y. and Pellman, D. (1997) APC-mediated proteolysis of Ase1 and the morphogenesis of the mitotic spindle. *Science*, **275**, 1311-1314.
- King, R.W., Peters, J.M., Tugendreich, S., Rolfe, M., Hieter, P. and Kirschner, M.W. (1995) A 20S complex containing CDC27 and CDC16 catalyzes the mitosis-specific conjugation of ubiquitin to cyclin B. *Cell*, **81**, 279-288.
- King, R.W., Deshaies, R.J., Peters, J.M. and Kirschner, M.W. (1996) How proteolysis drives the cell cycle. *Science*, **274**, 1652-1659.
- Kitamura, K., Maekawa, H. and Shimoda, C. (1998) Fission yeast Ste9, a homolog of Hct1/Cdh1 and Fizzy-related, is a novel negative regulator of cell cycle progression during G<sub>1</sub>-phase. *Mol. Biol. Cell*, **9**, 1065-1080.
- Kotani, S., Tugendreich, S., Fujii, M., Jorgensen, P.M., Watanabe, N., Hoog, C., Hieter, P. and Todokoro, K. (1998) PKA and MPF-activated polo-like kinase regulate anaphase-promoting complex activity and mitosis progression. *Mol. Cell*, **1**, 371-380.
- Kotani, S., Tanaka, H., Yasuda, H. and Todokoro, K. (1999) Regulation of APC activity by phosphorylation and regulatory factors. *J. Cell Biol.*, **146**, 791-800.

- Kramer,E.R., Scheuringer,N., Podtelejnikov,A.V., Mann,M. and Peters,J.M. (2000) Mitotic regulation of the APC activator proteins CDC20 and CDH1. *Mol. Biol. Cell*, **11**, 1555–1569.
- Lakin,N.D. and Jackson,S.P. (1999) Regulation of p53 in response to DNA damage. *Oncogene*, **18**, 7644–7655.
- Lane,M.E., Sauer,K., Wallace,K., Jan,Y.N., Lehner,C.F. and Vaessin,H. (1996) Dacapo, a cyclin-dependent kinase inhibitor, stops cell proliferation during *Drosophila* development. *Cell*, **87**, 1225–1235.
- Lengauer,C., Kinzler,K.W. and Vogelstein,B. (1998) Genetic instabilities in human cancers. *Nature*, **396**, 643–649.
- Lim,H.H., Goh,P.Y. and Surana,U. (1998) Cdc20 is essential for the cyclosome-mediated proteolysis of both Pds1 and Clb2 during M phase in budding yeast. *Curr. Biol.*, **8**, 231–234.
- Lorca,T., Castro,A., Martinez,A.M., Vigneron,S., Morin,N., Sigrist,S., Lehner,C., Doree,M. and Labbe,J.C. (1998) Fizzy is required for activation of the APC/cyclosome in *Xenopus* egg extracts. *EMBO J.*, **17**, 3565–3575.
- Lukas,C., Sorensen,C.S., Kramer,E., Santoni-Rugiu,E., Lindeneg,C., Peters,J.M., Bartek,J. and Lukas,J. (1999) Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex. *Nature*, **401**, 815–818.
- Muschel,R.J., Zhang,H.B. and McKenna,W.G. (1993) Differential effect of ionizing radiation on the expression of cyclin A and cyclin B in HeLa cells. *Cancer Res.*, **53**, 1128–1135.
- Nourse,J., Firpo,E., Flanagan,W.M., Coats,S., Polyak,K., Lee,M.H., Massague,J., Crabtree,G.R. and Roberts,J.M. (1994) Interleukin-2-mediated elimination of the p27<sup>Kip1</sup> cyclin-dependent kinase inhibitor prevented by rapamycin. *Nature*, **372**, 570–573.
- Pfleger,C.M. and Kirschner,M.W. (2000) The KEN box: an APC recognition signal distinct from the D box targeted by Cdh1. *Genes Dev.*, **14**, 655–65.
- Polyak,K., Lee,M.H., Erdjument-Bromage,H., Koff,A., Roberts,J.M., Tempst,P. and Massague,J. (1994a) Cloning of p27<sup>Kip1</sup>, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. *Cell*, **78**, 59–66.
- Polyak,K., Kato,J.Y., Solomon,M.J., Sherr,C.J., Massague,J., Roberts,J.M. and Koff,A. (1994b) p27<sup>Kip1</sup>, a cyclin-Cdk inhibitor, links transforming growth factor- $\beta$  and contact inhibition to cell cycle arrest. *Genes Dev.*, **8**, 9–22.
- Resnitzky,D., Hengst,L. and Reed,S.I. (1995) Cyclin A-associated kinase activity is rate limiting for entrance into S phase and is negatively regulated in G<sub>1</sub> by p27<sup>Kip1</sup>. *Mol. Cell Biol.*, **15**, 4347–4352.
- Schwab,M., Lutum,A.S. and Seufert,W. (1997) Yeast Hct1 is a regulator of Clb2 cyclin proteolysis. *Cell*, **90**, 683–693.
- Shirayama,M., Toth,A., Galova,M. and Nasmyth,K. (1999) APC(Cdc20) promotes exit from mitosis by destroying the anaphase inhibitor Pds1 and cyclin Clb5. *Nature*, **402**, 203–207.
- Sigrist,S.J. and Lehner,C.F. (1997) *Drosophila* fizzy-related down-regulates mitotic cyclins and is required for cell proliferation arrest and entry into endocycles. *Cell*, **90**, 671–681.
- Sonoda,E., Sasaki,S., Buerstedde,J.M., Bezzubova,O., Shinohara,A., Ogawa,H., Takata,M., Yamaguchi-Iwai,Y. and Takeda,S. (1998) Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. *EMBO J.*, **17**, 598–608.
- Sudakin,V., Ganoth,D., Dahan,A., Heller,H., Hershko,J., Luca,F.C., Ruderman,J.V. and Hershko,A. (1995) The cyclosome, a large complex containing cyclin-selective ubiquitin ligase activity, targets cyclins for destruction at the end of mitosis. *Mol. Biol. Cell*, **6**, 185–197.
- Takata,M. *et al.* (1998) Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. *EMBO J.*, **17**, 5497–5508.
- Uhlmann,F., Lottspeich,F. and Nasmyth,K. (1999) Sister-chromatid separation at anaphase onset is promoted by cleavage of the cohesin subunit Scc1. *Nature*, **400**, 37–42.
- Visintin,R., Prinz,S. and Amon,A. (1997) CDC20 and CDH1: a family of substrate-specific activators of APC-dependent proteolysis. *Science*, **278**, 460–463.
- Visintin,R., Craig,K., Hwang,E.S., Prinz,S., Tyers,M. and Amon,A. (1998) The phosphatase Cdc14 triggers mitotic exit by reversal of Cdk-dependent phosphorylation. *Mol. Cell*, **2**, 709–718.
- Wang,C.X., Fisk,B.C., Wadehra,M., Su,H. and Braun,J. (2000) Overexpression of murine fizzy-related (fzr) increases natural killer cell-mediated cell death and suppresses tumor growth. *Blood*, **96**, 259–263.
- Yamaguchi,S., Murakami,H. and Okayama,H. (1997) A WD repeat protein controls the cell cycle and differentiation by negatively regulating Cdc2/B-type cyclin complexes. *Mol. Biol. Cell*, **8**, 2475–2486.
- Yeong,F.M., Lim,H.H., Padmashree,C.G. and Surana,U. (2000) Exit from mitosis in budding yeast: biphasic inactivation of the Cdc28–Clb2 mitotic kinase and the role of Cdc20. *Mol. Cell*, **5**, 501–511.
- Zou,H., McGarry,T.J., Bernal,T. and Kirschner,M.W. (1999) Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. *Science*, **285**, 418–422.

Received January 31, 2001; revised August 31, 2001;  
accepted September 27, 2001